Page last updated: 2024-08-25

rosiglitazone and olaparib

rosiglitazone has been researched along with olaparib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Gao, J; Liu, H; Ohno, Y; Wang, Z; Xu, C	1

Other Studies

1 other study(ies) available for rosiglitazone and olaparib

Article	Year
Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib. Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:2 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Rosiglitazone; Tumor Suppressor Protein p53	2020

Article

Year

Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.

Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:2

Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phthalazines; Piperazines; Rosiglitazone; Tumor Suppressor Protein p53

2020